Revvity, Inc. (RVTY) fair value analysis
S&P 500 · Updated 2026-09-07
Revvity, Inc. is a healthcare company that provides analytical technologies, software, and services to researchers, clinicians, and diagnosticians across multiple end markets. The company operates globally, serving customers in the life sciences, diagnostics, and applied end markets throughout North America, Europe, Asia-Pacific, and other regions worldwide.
Forward Fair Value verdict
OvervaluedBased on TickrTrends' weekly Forward Fair Value model, RVTY is trading at a 10–25% premium to estimated fair value.
RVTY currently ranks #90 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Overvalued for 3 consecutive weekly runs.
- Last price
- $130.22
- Sector
- Healthcare
- 12-month range
- $86.68–$126.59
Derived indicators
Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.
- Quality grade
- A
- Leverage
- Low
- Margin trend
- Contracting
- Revenue growth
- Modest
- RSI zone
- Neutral
- 52-week position
- The top quarter of its range
- DCF cross-check
- Overvalued
What our data shows for RVTY
- Our model validated 17 trailing price-to-earnings windows for RVTY, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $86.68–$126.59.
- The 14-day relative strength index sits at a neutral 70.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for RVTY
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
How Forward Fair Value works
TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.
What people are saying
Follow the RVTY conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-06 — # RVTY Weekly Indicator Summary TickrTrends' derived indicators for RVTY showed notable shifts this week. The stock's momentum rating declined from B to none, while its RSI zone moved from overbought to neutral, suggesting reduced upward pressure and a moderation in price extremes. The current valuation verdict remains overvalued.
- 2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is RVTY stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), RVTY is trading at a 10–25% premium to estimated fair value and screens as overvalued. The exact fair value and discount are available to subscribers.
What is RVTY's TickrTrends verdict?
RVTY's current verdict is Overvalued, refreshed with every weekly Forward Fair Value run.
How does RVTY compare to other Healthcare stocks?
RVTY ranks #90 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.
Is RVTY overbought or oversold?
RVTY's 14-day RSI is in neutral territory - neither overbought nor oversold.
More in Healthcare
Head-to-head comparisons
RVTY vs BIIB · RVTY vs BIO · RVTY vs BVS · RVTY vs CVS · RVTY vs INMD